Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.
Zacks Investment Research on MSN10h
AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis StudyAmgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) ...
Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...
Clinical Trials Arena on MSN4d
Amgen’s gMG therapy cuts disease symptoms at one-year markResults from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom ...
US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).
Results from the company’s double-blind, placebo-controlled Mint study (NCT04524273) showed 72.3% of acetylcholine receptor autoantibody-positive (AChR+) gMG patients dosed with Uplizna saw a ...
72.3% of AChR+ patients on Uplizna saw a ≥3-point MG-ADL score improvement vs. 45.2% on placebo. Uplizna is under FDA priority review for IgG4-related disease with a PDUFA date of April 3.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback